• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Int J Epidemiol . Reduced mortality during the COVID-19 outbreak in Japan, 2020: a two-stage interrupted time-series design

tetano

Editor, Senior Moderator
Int J Epidemiol


. 2021 Oct 28;dyab216.
doi: 10.1093/ije/dyab216. Online ahead of print.
Reduced mortality during the COVID-19 outbreak in Japan, 2020: a two-stage interrupted time-series design


Daisuke Onozuka[SUP] 1 [/SUP], Yuta Tanoue[SUP] 2 3 [/SUP], Shuhei Nomura[SUP] 3 4 [/SUP], Takayuki Kawashima[SUP] 3 5 [/SUP], Daisuke Yoneoka[SUP] 3 4 6 [/SUP], Akifumi Eguchi[SUP] 3 7 [/SUP], Chris Fook Sheng Ng[SUP] 8 [/SUP], Kentaro Matsuura[SUP] 9 10 [/SUP], Shoi Shi[SUP] 11 12 [/SUP], Koji Makiyama[SUP] 10 [/SUP], Shinya Uryu[SUP] 13 [/SUP], Yumi Kawamura[SUP] 14 [/SUP], Shinichi Takayanagi[SUP] 10 [/SUP], Stuart Gilmour[SUP] 6 [/SUP], Takehiko I Hayashi[SUP] 15 [/SUP], Hiroaki Miyata[SUP] 3 [/SUP], Francesco Sera[SUP] 16 [/SUP], Tomimasa Sunagawa[SUP] 17 [/SUP], Takuri Takahashi[SUP] 17 [/SUP], Yuuki Tsuchihashi[SUP] 17 [/SUP], Yusuke Kobayashi[SUP] 17 [/SUP], Yuzo Arima[SUP] 17 [/SUP], Kazuhiko Kanou[SUP] 17 [/SUP], Motoi Suzuki[SUP] 17 [/SUP], Masahiro Hashizume[SUP] 4 [/SUP]



Affiliations

Abstract

Background: Coronavirus disease 2019 (COVID-19) continues to be a major global health burden. This study aims to estimate the all-cause excess mortality occurring in the COVID-19 outbreak in Japan, 2020, by sex and age group.
Methods: Daily time series of mortality for the period January 2015-December 2020 in all 47 prefectures of Japan were obtained from the Ministry of Health, Labour and Welfare, Japan. A two-stage interrupted time-series design was used to calculate excess mortality. In the first stage, we estimated excess mortality by prefecture using quasi-Poisson regression models in combination with distributed lag non-linear models, adjusting for seasonal and long-term variations, weather conditions and influenza activity. In the second stage, we used a random-effects multivariate meta-analysis to synthesize prefecture-specific estimates at the nationwide level.
Results: In 2020, we estimated an all-cause excess mortality of -20 982 deaths [95% empirical confidence intervals (eCI): -38 367 to -5472] in Japan, which corresponded to a percentage excess of -1.7% (95% eCI: -3.1 to -0.5) relative to the expected value. Reduced deaths were observed for both sexes and in all age groups except those aged <60 and 70-79 years.
Conclusions: All-cause mortality during the COVID-19 outbreak in Japan in 2020 was decreased compared with a historical baseline. Further evaluation of cause-specific excess mortality is warranted.

Keywords: All-cause death; COVID-19; Japan; excess mortality; two-stage interrupted time-series design.
 
Back
Top Bottom